Michigan Elmiron Pigmentary Maculopathy injury lawyer
Since our initial coverage of the Elmiron litigation, the landscape has shifted dramatically. The bladder pain medication, once prescribed to hundreds of thousands of patients for interstitial cystitis, has been at the center of a sprawling multidistrict litigation (MDL) over allegations that its manufacturer, Janssen Pharmaceuticals, failed to warn users about the risk of pigmentary maculopathy—a potentially blinding retinal condition. In 2026, the settlement process is now largely defined by a structured framework, and we want to ensure our readers understand the precise criteria that determine eligibility and compensation.
Janssen’s 2024 Global Settlement Framework and the MDL 3075 Bellwether Impact
The turning point came in late 2024 when Janssen agreed to a global settlement framework to resolve the vast majority of pending cases in MDL 3075, presided over by Judge Brian R. Martinotti in the District of New Jersey. The settlement was heavily influenced by the outcomes of early bellwether trials, which tested the strength of plaintiff claims. In one notable bellwether, a jury awarded $4.5 million to a Florida woman who developed severe vision loss after taking Elmiron for over a decade. That verdict, combined with mounting evidence from retinal specialists, forced Janssen to negotiate a tiered settlement structure.
For the most current and official updates on the MDL proceedings, we always recommend consulting the court docket directly. You can find the master case file and settlement administration details at the Antiques Topic legal resource hub and cross-reference with the archived MDL information available at our archived reference page. The terms we outline here reflect the framework as it stands in early 2026.
Three Pillars of Settlement Eligibility: Duration, Dosage, and Objective Retinal Damage
To qualify for compensation under the current framework, plaintiffs must satisfy three core criteria that the court and Janssen’s claims administrators have standardized. These criteria are designed to separate cases with genuine drug-induced injury from those with unrelated retinal conditions. Here is the breakdown:
- Cumulative Exposure Duration: The plaintiff must have taken Elmiron for a minimum of two consecutive years. Cases involving shorter durations are generally excluded unless there is extraordinary evidence of rapid-onset maculopathy, which is rare. The average claimant in the settlement pool had been on the drug for 7 to 15 years.
- Minimum Cumulative Dosage: The total lifetime dose must exceed 1,000 grams of pentosan polysulfate sodium. This roughly equates to taking the standard 100 mg, three-times-daily dose for about nine years. Lower dosages are presumed less likely to cause the characteristic pigmentary changes.
- Objective Retinal Findings: This is the most critical hurdle. Claimants must provide spectral-domain optical coherence tomography (SD-OCT) scans and fundus autofluorescence (FAF) imaging that demonstrate a "paracentral ring of hyperautofluorescence" and thinning of the outer retinal layers—the hallmark signs of Elmiron toxicity. A diagnosis of "interstitial cystitis-associated maculopathy" without these specific imaging findings is insufficient.
Compensation Tiers and the 2026 Claims Timeline
The settlement uses a tiered matrix that assigns base awards based on the severity of vision loss, measured by best-corrected visual acuity (BCVA) in the better-seeing eye. Additional multipliers are applied for bilateral involvement, the presence of secondary choroidal neovascularization, and the age of the plaintiff. Below is the current compensation schedule as administered by the claims facility:
| Severity Tier | BCVA in Better Eye | Base Award Range | Typical Multipliers Applied |
|---|---|---|---|
| Mild | 20/40 to 20/60 | $25,000 - $75,000 | 1.0x - 1.5x |
| Moderate | 20/70 to 20/200 | $100,000 - $250,000 | 1.5x - 2.0x |
| Severe | 20/200 to 20/400 | $300,000 - $600,000 | 2.0x - 3.0x |
| Profound | 20/400 or worse | $700,000 - $1,200,000 | 3.0x - 5.0x |
As of our latest update in March 2026, the claims window remains open for plaintiffs who filed their lawsuits before the October 2024 cutoff date. Those who did not file by that deadline are generally barred from the global settlement, though a small number of late-filed claims are being considered on a case-by-case basis if the plaintiff can demonstrate extraordinary circumstances, such as a recent diagnosis that was impossible to detect earlier. We strongly advise any potential claimant to verify their filing status with their attorney immediately, as the appeals process for denied claims is set to conclude by the end of this year.